Dimerization of FGFR1 fusion proteins 8p11 myeloproliferative syndrome (EMS) is a myeloproliferative disorder that rapidly progresses to acute myeloid leukemia if not treated (reviewed in Jackson, 2010, Knights and Cook, 2010). A characteristic feature of EMS is the presence of fusion proteins that contain the kinase domain of FGFR1 and the oligomerization domain of an unrelated protein. This is believed to promote the ligand independent dimerization and activation of the kinase domain. To date, there are 11 identified partners that form fusion proteins with FGFR1 in EMS: ZMYM2 (Xiao, 1998; Popovici, 1998; Reiter, 1998; Ollendorff, 1999; Xiao, 2000), FGFR1OP1 (Popovici, 1999), CNTRL (Guasch, 2000), BCR (Demiroglu, 2001), FGFR1OP2 (Grand, 2004), TRIM24 (Belloni, 2005), CUX1 (Wasag, 2011), MYO18A (Walz, 2005), CPSF6 (Hidalgo-Curtis, 2008), HERV-K (Guasch, 2003) and LRRFIP1 (Soler, 2009). Authored: Rothfels, K, 2012-02-09 Edited: Rothfels, K, 2012-05-16 Pubmed10480903 Pubmed10688839 Pubmed10887137 Pubmed11739186 Pubmed12393597 Pubmed15034873 Pubmed15609342 Pubmed15800673 Pubmed18205209 Pubmed19369959 Pubmed19874848 Pubmed20226962 Pubmed21330321 Pubmed9425908 Pubmed9576949 Pubmed9716603 Pubmed9949182 Reactome Database ID Release 431839031 Reactome, http://www.reactome.org ReactomeREACT_120809 Reviewed: Ezzat, S, 2012-05-15 has a Stoichiometric coefficient of 2 FGFR1 fusion mutant dimers FGFR1 fusion mutants